Acylated indanyl amines and their use as pharmaceuticals

Details Acylated indanyl amines and their use as pharmaceuticals Acylated indanyl amines and their use as pharmaceuticals

2007-02-20

2007-02-20

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S436000

Reexamination Certificate

active

10073160

ABSTRACT:
The present invention relates to acylated indanyl amines according to the general formula (I)wherein R1–R4have the meanings given in the description, A is CH2, CHOH or CH—(C1–C3-alkyl), B is CH2or CH—(C1–C3-alkyl), and R5is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS), and may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

REFERENCES:
patent: 3565897 (1971-02-01), Heerdt et al.
patent: 4192888 (1980-03-01), Bondinell et al.
patent: 4474692 (1984-10-01), Oka et al.
patent: 5583221 (1996-12-01), Hu et al.
patent: 6617359 (2003-09-01), Wohlfart et al.
patent: 6759412 (2004-07-01), Strobel
patent: 6812253 (2004-11-01), Wohlfart et al.
patent: 6949556 (2005-09-01), Strobel et al.
patent: 2004/0082628 (2004-04-01), Strobel
patent: 2004/0092513 (2004-05-01), Strobel
patent: 2004/0110808 (2004-06-01), Strobel
patent: 2004/0225013 (2004-11-01), Strobel
patent: 2005/0054729 (2005-03-01), Strobel
patent: 2005/0101599 (2005-05-01), Zeiher
patent: 0399422 (1990-11-01), None
patent: 9071534 (1997-03-01), None
patent: 9255592 (1997-09-01), None
patent: WO 91/17162 (1991-11-01), None
patent: WO 95/30640 (1995-11-01), None
patent: WO 96/24588 (1996-08-01), None
patent: WO 97/06158 (1997-02-01), None
patent: WO 99/26927 (1999-06-01), None
patent: WO 99/47153 (1999-09-01), None
patent: WO 00/03746 (2000-01-01), None
patent: WO 00/51970 (2000-08-01), None
patent: WO 02/20530 (2002-03-01), None
patent: 6806875 (1969-03-01), None
Robert S. Atkinson et al., Ring-opening of Chiral N-(3,4-dihydro-4-oxoquinazolin-3-yl)-substituted azirdines (Q*-substituted aziridines): access to Q*-free chirons, Tetrahedron Letters 39 (1998) 497-500.
Joseph G. Cannon et al., Centrally Acting Emetics. 6. Derivatives of β-Naphthylamine and 2-Indanamine, Journal of Medicinal Chemistry, 1972, vol. 15, No. 4, 348-350.
Joseph G. Cannon et al., Conformationally Restricted Congeners of Dopamine Derived from 2-Aminoindan, Journal of Medicinal Chemistry, 1982, 25, 1442-1446.
Peter A. Crooks, A new synthesis of 2-aminoindanes, Chemistry and Industry, Jun. 15, 1974, 495.
E. Dornhege, Absolute Konfiguration der isomeren 2-Amino-indanole-(1) und 2-N-Isoindolinyl-indanole-(1), Liebigs Ann. Chem., 743, 42-49 (1971).
Endres et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, Jul. 1998, vol. 95, pp. 8880-8885.
Hong Hu et al., Synthesis and Protein Kinase C Inhibitory Activities of Indane Analogs of Balanol, Bioorganic & Medicinal Chemistry Letters, 1996, vol. 6, No. 8, pp. 973-978.
Charles F. Huebner et al., The Azodiformate Adduct of Indene and the Stereochemistry of Some 1,2-Disubstituted Indans, The Journal of Organic Chemistry, Apr. 1970, vol. 35, No. 4, 1149-1154.
Huige Li et al., Activation of Protein Kinase Cα and/or ε Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Molecular Pharmacology (1998), 53:630-637.
Béatrice Malapel-Andrieu et al., Palladium-Catalyzed Reactions of Indolic Triflate with Allylic Alcohols, Tetrahedron Letters 39 (1998) 39-42.
Moriyasu Masui et al., Stereoselective Synthesis of 1,2-Amino Alcohols by Asymmetric Borane Reduction of α-Oxoketoxime Ethers, Tetrahedron Letters 39 (1998) 5195-5198.
M. Colette et al., Étude Des Nitrosochlorures De L'Indéne Et De Ses Homologues, Ann. Chim. 1976, 269-276.
Masao Moroi et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, The Journal of Clinical Investigation, vol. 101, No. 6, Mar. 1998, 1225-1232.
Masafumi Nakayama et al., T786→C Mutation in the 5′-Flanking Region of the Endothelial Nitric Oxide Synthase Gene Is Associated With Coronary Spasm, Clinical Investigation and Reports, 2864-2870 (1999).
E. Schmitz et al., Epimination of Olefins by Means of 3,3-Pentamethyleneoxaziridine—A One-Step Synthesis of Azirdines, Khimiya Geterotsiklicheskikh Soedinenni, Dec. 1974, No. 12, pp. 1629-1638.
William C. Sessa et al., Chronic Exercise in Dogs Increases Coronary Vascular Nitric Oxide Production and Endothelial Cell Nitric Oxide Synthase Gene Expression, Circulation Research, 1994, 74:349-353.
Olivier Varenne, et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Human Gene Therapy 11:1329-1339 (Jun. 10, 2000).
Maurice Colette et al., 209. Etude de l'action de l'oxyde d'azote (III) sur l'indéne et ses homologues, Helvetica Chimica Acta, vol. 60, Fasc. 6 (1977) 2089-2098.

Affiliated with

Also associated with

Rating

Acylated indanyl amines and their use as pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acylated indanyl amines and their use as pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated indanyl amines and their use as pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3832522